SIHUAN PHARM (00460): Innovative Drug Anjiuwei® Successfully Renewed in 2025 National Reimbursement Drug List

Stock News

Dec 08

SIHUAN PHARM (00460) announced that, following a simplified renewal negotiation with the National Healthcare Security Administration, its non-wholly owned subsidiary Xuanzhu Biotech's self-developed innovative drug Anaprazole Sodium Enteric-coated Tablets (brand name: Anjiuwei®) will continue to be included in the updated National Reimbursement Drug List (NRDL) for 2025, effective from January 1, 2026.

As the first and only domestically developed proton pump inhibitor in China, Anjiuwei® was approved in June 2023 for treating duodenal ulcers and first included in the NRDL in December 2023. The successful renewal of Anjiuwei® in the 2025 NRDL is expected to stabilize market sales, benefit more patients, enhance the drug's penetration rate in relevant indications, and drive long-term growth for the product.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1159093371"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1159093371\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1159093371?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-08 16:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1159093371","market":"hk","top_or_hot":-1,"title":"SIHUAN PHARM (00460): Innovative Drug Anjiuwei® Successfully Renewed in 2025 National Reimbursement Drug List","media":"Stock News","content":"<p>SIHUAN PHARM (00460) announced that, following a simplified renewal negotiation with the National Healthcare Security Administration, its non-wholly owned subsidiary Xuanzhu Biotech's self-developed innovative drug Anaprazole Sodium Enteric-coated Tablets (brand name: Anjiuwei®) will continue to be included in the updated National Reimbursement Drug List (NRDL) for 2025, effective from January 1, 2026.</p>\n<p>As the first and only domestically developed proton pump inhibitor in China, Anjiuwei® was approved in June 2023 for treating duodenal ulcers and first included in the NRDL in December 2023. The successful renewal of Anjiuwei® in the 2025 NRDL is expected to stabilize market sales, benefit more patients, enhance the drug's penetration rate in relevant indications, and drive long-term growth for the product.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SIHUAN PHARM (00460): Innovative Drug Anjiuwei® Successfully Renewed in 2025 National Reimbursement Drug List</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSIHUAN PHARM (00460): Innovative Drug Anjiuwei® Successfully Renewed in 2025 National Reimbursement Drug List\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-08 16:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SIHUAN PHARM (00460) announced that, following a simplified renewal negotiation with the National Healthcare Security Administration, its non-wholly owned subsidiary Xuanzhu Biotech's self-developed innovative drug Anaprazole Sodium Enteric-coated Tablets (brand name: Anjiuwei®) will continue to be included in the updated National Reimbursement Drug List (NRDL) for 2025, effective from January 1, 2026.</p>\n<p>As the first and only domestically developed proton pump inhibitor in China, Anjiuwei® was approved in June 2023 for treating duodenal ulcers and first included in the NRDL in December 2023. The successful renewal of Anjiuwei® in the 2025 NRDL is expected to stabilize market sales, benefit more patients, enhance the drug's penetration rate in relevant indications, and drive long-term growth for the product.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1593","symbol_name":"医美概念股","start_time":0,"source_url":"","article_id":"1159093371","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1159093371","pubTimestamp":1765183723,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"SIHUAN PHARM (00460) announced that, following a simplified renewal negotiation with the National Healthcare Security Administration, its non-wholly owned subsidiary Xuanzhu Biotech's self-developed...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159992":"创新药","BK1593":"医美概念股","BK1574":"生物医药B类股","BK1600":"工业大麻","00460":"四环医药","BK1515":"抗疫概念","BK1191":"制药","06978":"永泰生物-B","BK1161":"生物科技"},"translate_title":"四环医药（00460）：创新药安久维®成功续展2025年国家报销药品目录","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"06978":1,"00460":1},"content_text":"SIHUAN PHARM (00460) announced that, following a simplified renewal negotiation with the National Healthcare Security Administration, its non-wholly owned subsidiary Xuanzhu Biotech's self-developed innovative drug Anaprazole Sodium Enteric-coated Tablets (brand name: Anjiuwei®) will continue to be included in the updated National Reimbursement Drug List (NRDL) for 2025, effective from January 1, 2026.\nAs the first and only domestically developed proton pump inhibitor in China, Anjiuwei® was approved in June 2023 for treating duodenal ulcers and first included in the NRDL in December 2023. The successful renewal of Anjiuwei® in the 2025 NRDL is expected to stabilize market sales, benefit more patients, enhance the drug's penetration rate in relevant indications, and drive long-term growth for the product.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}